MAD2L2 Antibody

1. results provide insights into the structure of the Rev1/Polzeta TLS assembly and highlight the function of Rev7 homo- and heterodimerization. PMID: 30111544
2. Skp2, a confirmed APC/C-CDH1 substrate and E-cadherin destroyer, was increased in TGF-beta1-treated proximal tubular epithelial cells, which could be blocked by MAD2B depletion. PMID: 27488450
3. structure-based interaction analyses revealed an unprecedented mechanism involving CAMP's WK motif. Surprisingly, in one of the crystal forms, the MAD2L2-CAMP complex formed a dimeric structure in which the C-terminal region of MAD2L2 was swapped and adopted an immature structure PMID: 28887307
4. REV7 is a previously undescribed FA gene, which we term FANCV PMID: 27500492
5. Knockdown of REV7 inhibited the migration, invasion, and epithelial-mesenchymal transition (EMT) of breast cancer cells. Meanwhile, overexpression of REV7 promoted the migration, invasion, and EMT of breast cancer cells. PMID: 27712588
6. hMAD2 also binds to the hREV7-binding sequence in hREV3, whereas hMAD2 does not bind to a similar sequence in ADAM9 or ELK-1 and hREV7 does not bind to the hMAD2-binding sequence in hMAD1 or hCDC20. PMID: 20088965
7. data establish MAD2L2 as a crucial contributor to the control of DNA repair activity by 53BP1 that promotes NHEJ by inhibiting 5' end resection downstream of RIF1 PMID: 25799990
8. results reveal an unexpected crucial function of REV7 downstream of 53BP1 in coordinating pathological DSB repair pathway choices in BRCA1-deficient cells PMID: 25799992
9. that MAD2B may play an important role in high glucose-mediated podocyte injury of diabetic nephropathy via modulation of Cdh1, cyclin B1, and Skp2 expression PMID: 25651564
10. Rev7 is essential for mutagenesis and S phase progression in UV-irradiated fibroblasts. PMID: 18295554
11. These findings indicate that depletion of REV7 enhances sensitivity to cisplatin treatment in ovarian clear cell carcinoma (CCC), suggesting that REV7 is a candidate molecular target in CCC management. PMID: 24597627
12. MAD2L2 helps to ensure a robustly bistable switch between APC/C(CDC20) and APC/C(CDH1) during the metaphase-to-anaphase transition, thereby contributing to mitotic fidelity. PMID: 24100295
13. REV7 is required for anaphase-promoting complex-dependent ubiquitination and degradation of translesion DNA polymerase REV1. PMID: 23287467
14. MAD2B may mediate Sim2 function during development in CNS and thereby play a critical role in pathophysiological mechanisms in Down syndrome PMID: 22660985
15. analysis of the crystal structure of the ternary complex composed of the C-terminal domain of human REV1, REV7, and a REV3 fragment PMID: 22859296
16. the Rev1 C-terminal domain utilizes independent interaction interfaces to simultaneously bind a fragment of the 'inserter' poleta and Rev7 subunit of the 'extender' polvarsigma, thereby serving as a cassette that may accommodate several polymerases PMID: 22828282
17. ternary complex of the C-terminal domain of human REV1 in complex with REV7 bound to a REV3 fragment has been crystallized. The crystals belonged to space group P3(1)21, with unit-cell parameters a = b = 74.7, c = 124.5 A PMID: 22869133
18. The REV1/Polzeta complex maintains genomic stability by directly participating in DNA double-stranded break repair. PMID: 21926160
19. Data show that MAD2B interacts with CLTA during the G2/M phase of the cell cycle and that depletion of MAD2B leads to a marked increase in the percentage of misaligned chromosomes and a redistribution of CLTA during mitosis. PMID: 21152103
20. The hRev7 is required for TLS past BPDE-induced DNA lesions but that it is not essential for inserting nucleotides opposite such lesions suggest a role for hPolzeta in the extension step of translesion synthesis. PMID: 21143968
21. show the first crystal structure of REV7 in complex with a fragment of REV3 polymerase (residues 1847-1898) and reveal the mechanism underlying REV7-REV3 interaction PMID: 20164194
22. To clarify the structural basis of the interaction between REV7 and REV3, REV7 was crystallized in complex with a REV3 fragment. PMID: 20054135
23. the small GTPase RAN is a novel MAD2B binding protein PMID: 19753112
24. purified human REV1 and REV7 proteins form a heterodimer in solution, which is stable through intensive purification steps. PMID: 12529368
25. Upregulated MAD2L2 expression is associated with colorectal tumors PMID: 17044027
26. Human Rev7 (hRev7)/MAD2B/MAD2L2 is an interaction partner for Elk-1 and hRev7 acts to promote Elk-1 phosphorylation by the c-Jun N-terminal protein kinase (JNK) MAP kinases. PMID: 17296730
27. Chromophobe renal cell carcinoma presented underexpression of MAD1, and MAD2L2. PMID: 17333263
28. Hepatocellular carcinoma-associated gene 2 interacts with MAD2L2. PMID: 17541814
29. Study provides the first evidence for the involvement of MAD2B in TCF4-mediated epithelial-mesenchymal transdifferentiation. PMID: 19443654

Show More

Hide All

HGNC: 6764

OMIM: 604094

KEGG: hsa:10459

STRING: 9606.ENSP00000235310

UniGene: Hs.19400